8-K filing — Tonix Pharmaceuticals Holding Corp. (TNXP)
Filed: 2026-09-08 AccNo: 0001493152-26-041689 Size: 250 KB Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits
Stocks · News reference
Tonix Pharma Receives Official Minutes From Type C Meeting With FDA To Discuss Plans For Adaptive Phase 2 Field Study Of TNX-4800 To Prevent Lyme Disease In Adults In US
Alignment with FDA on key elements of the study design support planned start of the Phase 2 study in the first quarter of 2027Long-acting monoclonal antibody TNX-4800 is a rapidly acting alternative to vaccination
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Tonix Pharmaceuticals Q2 EPS $(2.44) Beats $(2.64) Estimate, Sales $13.544M Beat $7.723M Estimate
Tonix Pharmaceuticals (NASDAQ:TNXP) reported quarterly losses of $(2.44) per share which beat the analyst consensus estimate of $(2.64) by 7.58 percent. This is a 36.79 percent increase over losses of $(3.86) per share
Tonix Pharma Announces Publication Of Monkeypox Study In Journal Of Virology, Peer-Reviewed Publication Of ASM
Data show clade IIb from 2022 outbreak is 100 to 100,000-fold less virulent than clade IIa from 2003 outbreakThree new models for investigating mpox infection and pathogenesis identifiedTonix is advancing TNX-801, a